These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34423904)

  • 41. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
    Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
    Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial.
    Mathew SJ; Murrough JW; aan het Rot M; Collins KA; Reich DL; Charney DS
    Int J Neuropsychopharmacol; 2010 Feb; 13(1):71-82. PubMed ID: 19288975
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study.
    Li CT; Chen MH; Lin WC; Hong CJ; Yang BH; Liu RS; Tu PC; Su TP
    Hum Brain Mapp; 2016 Mar; 37(3):1080-90. PubMed ID: 26821769
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
    Newport DJ; Carpenter LL; McDonald WM; Potash JB; Tohen M; Nemeroff CB;
    Am J Psychiatry; 2015 Oct; 172(10):950-66. PubMed ID: 26423481
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression.
    Cornwell BR; Salvadore G; Furey M; Marquardt CA; Brutsche NE; Grillon C; Zarate CA
    Biol Psychiatry; 2012 Oct; 72(7):555-61. PubMed ID: 22521148
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression.
    Sos P; Klirova M; Novak T; Kohutova B; Horacek J; Palenicek T
    Neuro Endocrinol Lett; 2013; 34(4):287-93. PubMed ID: 23803871
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial.
    Lenze EJ; Farber NB; Kharasch E; Schweiger J; Yingling M; Olney J; Newcomer JW
    World J Biol Psychiatry; 2016 Apr; 17(3):230-8. PubMed ID: 26919405
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial.
    Irwin SA; Iglewicz A; Nelesen RA; Lo JY; Carr CH; Romero SD; Lloyd LS
    J Palliat Med; 2013 Aug; 16(8):958-65. PubMed ID: 23805864
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial.
    Arkell TR; Vinckenbosch F; Kevin RC; Theunissen EL; McGregor IS; Ramaekers JG
    JAMA; 2020 Dec; 324(21):2177-2186. PubMed ID: 33258890
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept.
    Rodriguez CI; Kegeles LS; Levinson A; Feng T; Marcus SM; Vermes D; Flood P; Simpson HB
    Neuropsychopharmacology; 2013 Nov; 38(12):2475-83. PubMed ID: 23783065
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments.
    Kadriu B; Musazzi L; Henter ID; Graves M; Popoli M; Zarate CA
    Int J Neuropsychopharmacol; 2019 Feb; 22(2):119-135. PubMed ID: 30445512
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate.
    Downey D; Dutta A; McKie S; Dawson GR; Dourish CT; Craig K; Smith MA; McCarthy DJ; Harmer CJ; Goodwin GM; Williams S; Deakin JF
    Eur Neuropsychopharmacol; 2016 Jun; 26(6):994-1003. PubMed ID: 27133029
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics and psychomotor performance of alprazolam: concentration-effect relationship.
    Wright CE; Sisson TL; Fleishaker JC; Antal EJ
    J Clin Pharmacol; 1997 Apr; 37(4):321-9. PubMed ID: 9115058
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression.
    Xu AJ; Niciu MJ; Lundin NB; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Machado-Vieira R; Zarate CA
    Neural Plast; 2015; 2015():858251. PubMed ID: 26137324
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of simulated driving in comparison to laboratory-based tests to assess the pharmacodynamics of alprazolam and alcohol.
    Huizinga CR; Zuiker RG; de Kam ML; Ziagkos D; Kuipers J; Mejia Y; van Gerven JM; Cohen AF
    J Psychopharmacol; 2019 Jul; 33(7):791-800. PubMed ID: 30912701
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Analgesic Effect of Intraoperative Intravenous S-Ketamine in Opioid-Naïve Patients After Major Lumbar Fusion Surgery Is Temporary and Not Dose-Dependent: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Brinck ECV; Maisniemi K; Kankare J; Tielinen L; Tarkkila P; Kontinen VK
    Anesth Analg; 2021 Jan; 132(1):69-79. PubMed ID: 32167978
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Using alcohol intoxication goggles (Fatal Vision® goggles) to detect alcohol related impairment in simulated driving.
    McCartney D; Desbrow B; Irwin C
    Traffic Inj Prev; 2017 Jan; 18(1):19-27. PubMed ID: 27260944
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Repeated and escalating preoperative subanesthetic doses of ketamine for postoperative pain control in patients undergoing tumor resection: a randomized, placebo-controlled, double-blind trial.
    Rakhman E; Shmain D; White I; Ekstein MP; Kollender Y; Chazan S; Dadia S; Bickels J; Amar E; Weinbroum AA
    Clin Ther; 2011 Jul; 33(7):863-73. PubMed ID: 21722959
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB
    JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessment of Relationship of Ketamine Dose With Magnetic Resonance Spectroscopy of Glx and GABA Responses in Adults With Major Depression: A Randomized Clinical Trial.
    Milak MS; Rashid R; Dong Z; Kegeles LS; Grunebaum MF; Ogden RT; Lin X; Mulhern ST; Suckow RF; Cooper TB; Keilp JG; Mao X; Shungu DC; Mann JJ
    JAMA Netw Open; 2020 Aug; 3(8):e2013211. PubMed ID: 32785636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.